Jay Lichter

This profile gathers the share dealings of Jay Lichter across 4 companies, led by Otonomy, Inc., Janux Therapeutics, Inc. and Synthorx, Inc. The record holds 52 filings, for trades running from 2 July 2013 to 13 September 2024.

Both buying and selling appear: 5 purchases worth €22.4M, against 20 sales worth €93.1M. On balance, insiders were net sellers of €70.7M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 3 share grants and 5 option exercises. 2024 to date brings no purchases and 4 sales.

In size, the median ticket on the buying side is €4.7M. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 24 October 2024 with an option exercise (€7,536) in Janux Therapeutics, Inc. The most recent open-market purchase was published on 15 November 2023, 1,074 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.